Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase Family: Novel Prognostic Biomarkers and Tumor Microenvironment Regulators for Lower-Grade Glioma

Siming Gong; Changwu Wu; Franziska Köhler; Jürgen Meixensberger; Nikolas Schopow; Sonja Kallendrusch

doi:10.3389/fncel.2022.838548

Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase Family: Novel Prognostic Biomarkers and Tumor Microenvironment Regulators for Lower-Grade Glioma

Front Cell Neurosci. 2022 Feb 18:16:838548. doi: 10.3389/fncel.2022.838548. eCollection 2022.

Authors

Siming Gong¹, Changwu Wu¹, Franziska Köhler¹, Jürgen Meixensberger², Nikolas Schopow^{1

3}, Sonja Kallendrusch^{1

4}

Affiliations

¹ Institute of Anatomy, University of Leipzig, Leipzig, Germany.
² Department of Neurosurgery, University Hospital Leipzig, Leipzig, Germany.
³ Department of Orthopedics, Trauma and Plastic Surgery, Sarcoma Center, University Hospital Leipzig, Leipzig, Germany.
⁴ Department of Medicine, Health and Medical University Potsdam, Potsdam, Germany.

Abstract

Lower-grade glioma (LGG) is a group of tumors arising from the cells of the central nervous system. Although various therapy interventions are used, the prognosis remains different. Novel biomarkers are needed for the prognosis of disease and novel therapeutic strategies in LGG. The procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD) family contains three members and is related to multiple cancers, yet it was not investigated in LGG. Data from the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) cohorts were used to analyze the role of PLOD in LGG. As the PLOD family is involved in processes, such as tumor formation and cancer metastasis, we focused on its relationship to the tumor microenvironment (TME) in LGG. A high expression of the PLOD family relates to poor prognosis and high infiltration of immune cells within the TME. The expression level of the PLOD family might become a novel biomarker for prognosis and is a potential target for individual treatment decisions in LGG.

Keywords: PLOD family; immune infiltration; immunotherapy; lower-grade glioma; prognosis; tumor microenvironment.